(R)-CTX-712 is a potent inhibitor of cdc2-like kinase (CLK). (R)-CTX-712 inhibits CLK kinase activity, and thus inhibits cancer survival and cancer cell growth. (R)-CTX-712 has the potential for the research of cancer disease (extracted from patent JPWO2017188374A1, compound 286).

Product information

CAS Number: 2144751-78-8

Molecular Weight: 408.39

Formula: C19H17FN8O2

Smiles: CC1=NC2=NC=C(C=C2N1CC1=NN=C(O1)[C@@H](C)F)C1C=CN2N=CN=C(OC)C2=1

InChiKey: OENNTZBJPRRGFL-SNVBAGLBSA-N

InChi: InChI=1S/C19H17FN8O2/c1-10(20)18-26-25-15(30-18)8-27-11(2)24-17-14(27)6-12(7-21-17)13-4-5-28-16(13)19(29-3)22-9-23-28/h4-7,9-10H,8H2,1-3H3/t10-/m1/s1

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: To be determined

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

References:

1. Fused heterocyclic compounds. Patent JPWO2017188374A1.

Products are for research use only. Not for human use.